

Streamlining Immune Cell Profiling: Advanced Panel Design with Sartorius Antibodies and New iQue® HTS Platform

K. Dienst¹ and D. Cole^{2*}

¹Sartorius Lab Instruments, Goettingen, Germany,
²BioAnalytics, Sartorius (Essen BioScience), Royston, Hertfordshire, UK;
 *Corresponding author: Daryl.Cole@sartorius.com

Introduction

- As interest in CAR-T cells and immune-based oncology therapies increases, there is an increasing requirement for efficient and rapid phenotyping of potential cell therapy products.
- To address this demand, it is essential that both the instruments for cell interrogation and the supporting tools for panel design can flexibly accommodate the variety of required markers.
- This study highlights the application of Sartorius selected antibodies in conjunction with the Sartorius panel design tool to streamline the assay building process.
- When integrated with the next generation iQue® HTS cytometer platform this provides enhanced flexibility and expanded channel coverage.
- To showcase this workflow, data was generated for a T cell phenotyping panel and tested in PBMCs.


New iQue® 5 HTS platform

The new, next generation iQue® instrument builds on the established features of the existing iQue® 3 platform to enhance the customer experience and support extra flexibility.

Equipped with adaptable automation capabilities, it facilitates seamless integration with automation solutions, enhancing high-throughput screening and minimizing the need for manual intervention.

		Laser			
Emission Filter		405 nm	488 nm	561 nm	640 nm
445/45 nm	✓	Pacific Blue			
525/45 nm	✓	BV510	✓	FITC	
586/20 nm	✓	BV605	✓	EYFP	✓
615/20 nm	✓	Qdot 605	✓	PI	✓
667/30 nm	✓	BV650	✓	PerCP	✓
695/40 nm	✓	BV711	✓	PerCP-Cy5.5	✓
725/40 nm	✓	BV750	✓	PerCP-eFluor7	✓
780/60 nm	✓	BV786	✓	PE-Cy7	✓
					APC-Cy7

Table 1: Laser and channel details for iQue® 5 Platform



T Cell Panel Design

A comprehensive T cell panel was developed using the Sartorius panel tool (table 1 below).

- Two panels were designed for use on either iQue® 3 or 5 using a base panel covering CD3, CD4, CD8 and a viability marker.
- Further markers for activation (CD69, CD25), exhaustion (LAG-3, TIM-3, PD-1) or memory (CCR7, CD62L), were added for further characterization.
- Using the new iQue® 5 HTS platform a further 4 markers were incorporated to enable the capture of 11 data channels, along with forward and side scatter, from a 96-well plate.
- The addition of a fourth laser increases the flexibility for panel design and ability to capture more data.

Laser	Channel	Target	Fluorochrome	iQue®3 panel
Violet 405	V445/45	Viability	Zombie Violet	VL1 - 445/45
Violet 405	V525/45	CD8	BV510	VL2 - 530/30
Violet 405	V615/20	CD4	BV605	VL4 - 615/24
Violet 405	V780/60	CD69	BV786	
Blue 488	B525/45	CD62L	FITC	
Yellow 561	Y586/20	CD25	PE	BL2 - 572/28
Yellow 561	Y615/20	CCR7	PD-Dazzle594	
Yellow 561	Y780/60	PD-1	PECy7	BL5 - 780/60
Red 640	R667/30	LAG-3	AF647	RL1 - 675/30
Red 640	R695/30	TIM-3	APC	
Red 640	R780/60	CD3	APC-Fire750	RL2 - 780/60

Table 2: Predicted panel layout




Figure 1: Predicted panel layout across lasers for iQue® 5 Platform, note overlapping spectra for APC and AF647

Compensation Assessment

Initially, compensation particles were tested with the selected antibodies to automatically calculate compensation spillover values using iQue Forecyt® software, before applying the panel to immune cells.

- In iQue® 5, PE conjugated antibodies can use the yellow laser excitation for improved resolution.
- Spillover matrix highlights potential issue with TIM-3 and LAG-3 due to overlapping spectra.
- iQue Forecyt® compensation allows overlapping fluorophores to be isolated and successfully analyzed.




Table 3: Spillover Matrix generated in iQue® Forecyt Software on both iQue® 3 and iQue® 5.





Figure 2: Example compensation plots across lasers, demonstrating clear positive peak in selected channel.

Phenotype Profiling in PBMCs

Human PBMCs were cultured in RPMI 1640 media with 10% serum and IL-2, with or without CD3/CD28 T cell activation beads (1 bead per cell) to activate the T cell population. Over the following 72 hours, the cells were assessed using the panel.

Cells were assessed using the following strategy:

- All events to detect cells (FSC Vs SSC) and singlets (not shown)
- Viability marker for live cells
- CD3+ cells
- CD4+ and CD8+ populations



- A - Live, T cell populations at 48 h.
- B - Activation markers, plots show treatment groups for all cell events to highlight activated population.
- C - Bar graph compares activation at 48 and 72 h for each T cell population.

- Clearly see CD69, early marker for activation reducing by 72 h while CD25 remains high.
- D - Exhaustion marker plots show data for the live CD3+ population. These markers are known to show a transient increase after activation and at 48 h all three show some increase but unlikely to be true exhaustion.

- E - Displays potential memory phenotypes. Using CCR7 and CD62L it is possible to define two groups Tscm/Tcm (less differentiated) and Tem/Teff (more differentiated) populations. Post activation the CD3+ T cells have moved to more differentiated state (control 16%, activation 76%).

Conclusion

- In summary, the new iQue® 5 HTS platform provides several enhancements to support users, including increased flexibility in designing complex panels.
- The integration of Sartorius Antibodies, the panel design tool and the iQue® 5 HTS platform offers a streamlined approach for creating complex panels to profile immune cell populations.
- The panel can be expanded and further enhanced by incorporating cytokine profiling using the iQue Qbead® portfolio, leveraging the iQue® Platform's capacity to independently track both cell and bead populations within the same sample.

